EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC-ND 4.0

An individual participant meta‐analysis of mirabegron in multiple sclerosis and spinal cord injury

Blayne Welk, Jan Krhut, Radek Sýkora

Neurourology and Urodynamics · 2024

DOI: 10.1002/nau.25439 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Neurourology and Urodynamics, 2024. Verfasst von Blayne Welk und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Epidemiology and Biostatistics, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Multiple Sclerosis, Urinary Bladder, Neurogenic, Urinary Bladder, Overactive, Spinal Cord Injuries. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Our objective was to conduct an individual patient data meta‐analysis (IPDMA) of the two published randomized placebo‐controlled trials of mirabegron in people with neurogenic lower urinary tract dysfunction (NLUTD) due to spinal cord injury (SCI) or multiple sclerosis (MS).

Methods

We identified two randomized, placebo‐controlled trials. We extracted individual patient data from the trials and evaluated two primary outcomes: change in maximum cystometric capacity and change in the patient perception of bladder condition (PPBC). We also evaluated several secondary outcomes related to urodynamic function and quality of life. We conducted three exploratory analyses to test hypotheses based on our clinical experiences with mirabegron in NLUTD. Analysis of covariance with adjustment for baseline values was used for the statistical analysis.

Results

Our IPDMA included 98 patients from the two trials. The results showed that mirabegron was associated with a significant improvement in maximum cystometric capacity (+41 mL, p = 0.04) and in the PPBC (−0.8, p < 0.01) compared to placebo. Secondary outcomes including peak neurogenic detrusor overactivity pressure (−20 cm H 2 O, p < 0.01), incontinence‐QOL score (+12, p < 0.01), and 24 h pad weights (−79 g, p = 0.04) also improved significantly compared to placebo. Exploratory analyses found similar improvements in people with MS and SCI; some outcomes improved to a greater degree among people with incomplete SCI, or SCIs that were below T7.

Conclusions

Our IPDMA provides evidence supporting the use of mirabegron in patients with NLUTD due to SCI or MS. Further work evaluating differential responses in people with different SCI lesion characteristics may be warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisUrinary Bladder, NeurogenicUrinary Bladder, OveractiveSpinal Cord InjuriesAcetanilidesThiazolesHumansQuality of LifeTreatment OutcomeUrodynamics

Stichwörter der Autor:innen

mirabegronneurogenic bladderurodynamics

Substanzen

mirabegronAcetanilidesThiazoles

Autor:innen und Institutionen

  • Department of Surgery and Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
  • Department of Urology, University Hospital, Ostrava, Czech Republic.
  • Department of Surgical Studies, Ostrava University, Ostrava, Czech Republic.

Zitieren

APA

Welk, B., Krhut, J., & Sýkora, R. (2024). An individual participant meta‐analysis of mirabegron in multiple sclerosis and spinal cord injury. Neurourology and Urodynamics. https://doi.org/10.1002/nau.25439

Vancouver

Welk B, Krhut J, Sýkora R. An individual participant meta‐analysis of mirabegron in multiple sclerosis and spinal cord injury. Neurourology and Urodynamics. 2024. doi:10.1002/nau.25439

BibTeX
@article{Welk2024,
  author = {Welk, Blayne and Krhut, Jan and Sýkora, Radek},
  title = {An individual participant meta‐analysis of mirabegron in multiple sclerosis and spinal cord injury},
  journal = {Neurourology and Urodynamics},
  year = {2024},
  doi = {10.1002/nau.25439}
}
Kostenlos starten →